Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: ear disorder therapeutics - SALVAT

Drug Profile

Research programme: ear disorder therapeutics - SALVAT

Alternative Names: SVT-15652

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SALVAT
  • Class Antibacterials; Antifungals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ear disorders; Otitis externa

Most Recent Events

  • 05 Oct 2018 Preclinical development for Ear disorders is ongoing in Spain (Salvat website, October 2018)
  • 28 Sep 2018 Salvat plans a phase III CLEAR-1 trial for Otitis externa (Otic) in January 2019 (NCT03686384)
  • 28 Sep 2018 Salvat plans a phase III CLEAR-2 trial for Otitis externa (Otic) in March 2019 (NCT03686397)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top